Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 11/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL163163 | 0.87 | NAMPT (0.74) | NAMPTKMT2APOLBMEN1 | |
| SCHEMBL10290830 | 0.86 | POLB (0.71) | NAMPTKMT2APOLBMEN1 | |
| SCHEMBL164148 | 0.86 | NAMPT (1.00) | NAMPT | |
| SCHEMBL15529861 | 0.84 | NAMPT (0.83) | NAMPTKMT2AMEN1 | |
| SCHEMBL15530415 | 0.83 | NAMPT (0.77) | NAMPTKMT2APOLBMEN1 | |
| SCHEMBL15530100 | 0.83 | NAMPT (0.71) | NAMPTKMT2ATSHRPOLBMEN1 | |
| SCHEMBL15530533 | 0.83 | NAMPT (0.77) | NAMPTKMT2APOLBMEN1 | |
| SCHEMBL165598 | 0.83 | NAMPT (1.00) | NAMPT | |
| SCHEMBL15530182 | 0.81 | NAMPT (0.65) | NAMPTKMT2APOLBMEN1 | |
| SCHEMBL15530502 | 0.81 | NAMPT (0.77) | NAMPTKMT2APOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279687-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20200283403-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283403-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, HAMP, NQO1 | NAMPT 1/4885KMT2A 1299/4885TSHR 2416/4885 |
| US-11279687-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNT, NQO1 | NAMPT 1/4885KMT2A 659/4885TSHR 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.